Study Focus:

The VICTORIA study examined whether vericiguat (MK-1242), an oral soluble guanylate-cyclase stimulator, was more effective than a placebo in increasing the time to first occurrence of the composite of cardiovascular death or heart failure hospitalization in participants with heart failure with reduced ejection fraction (HFrEF).

Study Population:
5,050 randomized subjects with HFrEF at 683 sites in 42 countries.

Clinical Events Classification Insight:
Duke Clinical Research Institute provided Clinical Event Classification services for over 7,000 events adjudicated including death, cardiovascular-related
hospitalizations (heart failure, myocardial infarction, stroke, and other cardiovascular events) and urgent heart failure visits.